Brain distribution of the opiate receptor antag onist, cycIofoxy (CF), was evaluated at equilibrium in rats. A combination of i. v. injection and constant i. v. infusion was used to administer CF over a wide dose range (2.4-450 nmol/rat). Kinetic simulations and exper imental results showed that this administration schedule accomplishes "true" tissue-blood equilibrium of CF within 60 min. To estimate the receptor-ligand binding parameters, we assumed that the CF concentration at the receptor site is identical to that in plasma water at equi librium, and can be calculated from measured blood data after corrections for radiolabeled metabolites and plasma protein binding. This assumption was supported by CSF and plasma water measurements at equilibrium. Regional Kn, Bmax, and a nonspecific tissue binding equilibrium constant (Keq) were estimated by fitting the tissue and plasma water concentrations to a single receptor model; the estimated values were 1.4-2.9 nM, 15-74 pmol/g of tissue, and 5.2-8.0, respectively. They are in good agree-Abbreviations used: AIC, Akaike 's information criterion; a Administration by i.v. bolus and constant infusion; the dose by bolus injection (DBOd and the dose by constant infusion (D1NF/h) were in a fixed relationship (DBOLIDINF = 45/55 per h). b Calculated as the equilibrium value [Kawai et al . (l990b) and Eq. (15)].
BBB, blood-brain barrier; B/I, bolus/infu sion ratio; BP" recep tor binding potential; CF, cyclofoxy; ECF, extracellular fluid; EER, ethyl acetate extraction ratio; PET, positron emission to mography.
Abstracts of part of this work were presented at the XIV In ternational Symposium on Cerebral Blood Flow and Metabo lism, Bologna, Italy in June 1989 and at the 37th Annual Meeting of the Society of Nuclear Medicine, Washington, D.C. in June 1990 . 529 ment with previous in vitro measurements (Rothman and McLean, 1988) as well as in vivo estimates from i.v. in jection experiments (Sawada et aI., 1990c) . The conven tional method to estimate the receptor-ligand binding pa rameters using data from cerebellum to approximate non specific tissue binding was found to be unacceptable. Although cerebellum is a brain region with no opiate re ceptors in rats, small differences in nonspecific tissue binding in different brain regions resulted in significant overestimations of Kn and Bmax with this method. Recep tor-active and -inactive enantiomers [[18F] ( -)-CF and
[3H]( + )-CF)] were simultaneously administered to the same animal and the receptor-bound CF concentration could be accurately measured; this method was used to estimate Bmax from a single study in a single animal and has potential for direct application in human studies using positron emission tomography. Key Words: CycIofoxy Opiate antagonist-Enantiomers-Opiate receptor PET-Nonspecific binding-Kn-Bmax-Brain.
Various strategies have been presented for the kinetic analysis of neuroligand uptake in brain tis sue (Mintun et aI. , 1984 ; Frey et aI., 1985 ; Perlmut ter et aI. , 1986; Wong et aI. , 1986a .. Logan et aI. , 1987 Frost et aI., 1989) . All of these analyses re quire the estimation of trans capillary exchange, nonspecific binding, and receptor-ligand interac tion. In our previous studies, we have compared various kinetic models and discussed the limitations of different experimental paradigms. Differences in kinetic models, namely different assumptions for transcapillary exchange (Sawada et aI. , 1990a,c) and nonspecific tissue binding (Kawai et aI., 1990b) , could influence the estimation of the receptor binding parameters. By performing equilibrium studies of receptor-ligand binding, the effects of blood flow, blood-brain barrier (BBB) transport, time-dependent nonspecific binding (Frost et aI. , 1989 ; Kawai et aI. , 1990b) , and rapidly changing blood levels following i. v. injection are eliminated . Furthermore, data analysis will not be dependent on fitting time-activity data to specific compart ment models of ligand distribution and data acqui sition will be simplified; a single equilibrium mea surement is all that is required providing "true" tissue-blood equilibrium is achieved . The magni tudes of receptor binding and nonspecific tissue binding are the primary values obtained from an analysis of equilibrium experiments . Unfortunately, only a limited number of studies have addressed equilibrium-type analyses (Frey et a! ., 1984; Farde et a! ., 1986 Farde et a! ., , 1987 Farde et a! ., , 1989 Frost et a!., 1990; Swart et aI ., 1990 ) and a general approach for the practical implementation in vivo of equilibrium measure ments has not been established . This is understand able since many receptor-specific neuroligands have too high affinity to the receptor (or too Iow a dissociation rate from the receptor site) and tissue blood equilibrium is not obtainable within the ex perimental period.
The levorotary stereoisomer (-)-cy cIofoxy [( -)-CF] was synthesized (Brine and Kepler, 1976; Burke et aI ., 1985) and was shown to be a pure opiate antagonist without agonist properties (Aceto et aI., 1987) and binds to both mu and kappa sub types of the opiate receptor (Rothman and McLean, 1988) . We have shown that ( -)-CF has a rapid re ceptor dissociation rate; the in vivo dissociation rate constant ranged from 0.1-0.2 min -I in rat as determined by tracer (Kawai et aI ., 1990b) and low specific activity experiments (Sawada et aI ., 1990c) . The permeability of the BBB for CF was also found to be modestly high; the unidirectional extraction ratio ranged between 0.6-0.7 (Sawada et a!., 1990a; Kawai et aI., 1990a) . However, neither an indepen dent i. v. bolus injection nor a constant infusion pro duced "true tissue-blood equilibrium" within an experimental period of 60 min . These studies indi cate that a rapid dissociation rate of the ligand receptor complex and a high permeability of the BBB for the ligand may not be sufficient to establish true tissue-blood equilibrium.
In the present study, we adopted a combination of i.v. bolus injection and constant i.v. infusion to facilitate the establishment of true equilibrium: a tissue-blood steady state under constant blood lev els . This method was validated for (-)-CF and we show that the bolus-infusion approach can be used to obtain reliable measurements of Ko and Bmax . In our analysis, we also consider two relevant issues : how to define and measure the effective, free ligand concentration in brain tissue and how to accurately estimate or measure nonspecific tissue binding. We also present a new method that reliably estimates J Cereb Blood Flow Metab, Vol. 11, No. 4, 1991 Bmax from a single experiment using ( -)-CF and the receptor-inactive, dextrorotary isomer, (+ )-CF .
MATERIALS AND METHODS

Chemicals
Tritium-labeled cyclofoxy enantiomers, (+)and ( -H 15, 16-3H] 17-cyclopropylmethyl-3, I4-dihydroxy-4,5a-epoxy-6J3-fluoromorphinan, were prepared as de scribed previously for the (-) enantiomer (Burke et aI., 1985; Ostrowski et aI., 1987) . Specific activities of these two tritiated products were 24.5 and 20.5 Ci/mmol, re spectively.
Fluorine-I8 labeled (-)-CF was prepared from the 3-acetyl-6-a-naltrexol trifluoromethanesulphonate ester as previously described (Channing et aI., 1985) . The spe cific activity was in the range of 30-32 Cil/Lmol for the tracer study (experiment set A; see below) and ranged from 4.4 to 11.7 Ci//Lmol (before adding unlabeled com pound) for the saturation study (set D).
Radiochemical purity was measured by HPLC using a Beckman Ultrasphere ODS (5 /Lm, 4.6 cm i.d. x 25 cm) analytical column and acetonitrilell 0 mM phosphate buffer, pH 2. 1, which contains 10 mM dodecylsulfonic acid [35/36 (v/v)] as the elution solvent. Radiochemical purity was 9�99% and 98-99% for the tritium and 1s F compounds, respectively.
Animal experiments
Male Sprague-Dawley rats, weighing 260-420 g, were anesthetized [halothane/nitrous oxide/oxygen: 2.5/20/40 (v/v/v)]. Bilateral femoral artery and vein catheters (PE50, Clay Adams) were placed and the animals were immobi lized on a lead brick by applying a loose-fitting plaster bandage below the midthorax. The animals were allowed to recover from anesthesia for about 3 h prior to the ad ministration of isotopes. Arterial blood pressure was monitored before and during the experiment. Rectal tem perature was maintained at 3�37°C with radiant heat lamps. Arterial blood gases [PaC02, 37 ± 3.4 mm Hg (SD); Pa02, 89.7 ± 9.4 mm Hg] and pH (7.40 ± 0.04) were measured immediately prior to the experiment.
We performed four different sets of experiments to confirm the establishment of' 'true" tissue-blood equilib rium and to validate our equilibrium method to estimate KD and Bmax in vivo.
(A) Establishing tissue-blood equilibrium. Tracer [18F]( -)-CF was dissolved in normal saline (70-200 /LCi/mt); at the beginning of the experiment, 0.82 ml of this solution was injected i. v. and an i. v. constant infu sion of the same solution (l mllh) was started simulta neously. Blood samples were collected at 10, 20, 30, and 45 s and 1, 2, 3, 5, 10, 20, 30, 45, 60, 75 , and 90 min after the bolus injection and the rat was decapitated at 45, 60, or 90 min. The brain was rapidly removed and various structures of brain were obtained by dissection.
(B) Nonlinear in vivo receptor binding at equilibrium.
[3H]( -)-CF (55 /LCi/mt) and unlabeled (-)-CF (0-250 nmollmt) were dissolved in normal saline and the solution was administered to rats in the same manner as described above (A). Arterial blood samples were obtained at 30, 45, and 60 min. The rat was decapitated at 60 min and the brain was processed as described above.
(C) Comparison of "free", unbound ligands in plasma and CSF. The same mixture of CH]( -)-CF and unlabeled ( -)-CF as (B) was administered to another group of rats.
In an additional group of animals, [3HJ( + )-CF (55 fLCilml) without unlabeled ligand was administered as described above (A). The rats were anesthetized by a rapid i. v. injection of pentobarbital (20 mglrat) at 60 min; samples of arterial blood and CSF from the cisterna magna were obtained immediately. In this set of experiments, arterial blood samples were also obtained immediately (5-10 s) after CF administration and the unbound fraction (fp) of CF was measured by an ultrafiltration method (Kawai et aI., 1990a) .
(D) Simultaneous administration of receptor-active and -inactive enantiomers.
[18F]( -)-CF (70--200 fLCi/ml),
[3H]( + )-CF (55 fLCi/ml), and unlabeled (-)-CF (100--150 nmollml) were dissolved in normal saline. The same ex perimental schedule as (B) was performed with this iso tope solution.
Measurement of radioactivity
18F radioactivity in tissue, blood, and plasma samples from experiment sets A and D were measured by gamma counting (Packard, model A5530) with simultaneous de cay correction. Tissue mass was determined by weight; blood and plasma volume were measured by micropipet. A tissue solubilizer (NCS, Amersham-Searle Co.) was added to all of the samples, and the samples were incu bated at 50°C for 4-8 h to achieve complete digestion. Blood samples were decolorized with benzoyl peroxide (20 mg/fLl of blood). A toluene-based liquid scintillator (liquifuor, New England Nuclear) was added and 3H ac tivity was measured by liquid scintillation counting (Pack ard, model A-4530D). All of samples were stored in the refrigerator for at least 48 h prior to 3H counting to elim inate chemical luminescence, as well as to allow for com plete decay of I�F activity in experiment set D.
Measurement of unchanged CF in plasma and blood
The fraction of plasma radioactivity representing un changed or parent CF was determined according to an ethyl acetate extraction method as previously described (Blasberg et aI., 1989; Kawai et aI., 1990a) . The ethyl acetate extraction ratio of plasma activity (EER) was cal culated by where DPM, Vs, and Vo are the measured radioactivity, sampled volume for radioactivity assay, and the original volume of the organic or aqueous layers used for the ex traction, respectively; SUbscripts I and 2 refer to the ethyl acetate and the aqueous layer, respectively. The fraction of radioactivity in plasma representing unchanged CF (F C F) was obtained by
where EERo is the EER value of the control plasma sam ple and was obtained by adding a small amount of infusate to a plasma sample obtained from each rat just prior to the experiment (the control value ranged between 0.95-0.99 for all of the labeled compounds).
The corrected arterial blood concentration of CF (Cb) was calculated from the unchanged fraction in plasma, F CF' the measured plasma activity (C;), and blood to-plasma concentration ratio (Rb) of unchanged CF:
(3)
The Rb ratio for both ( -) and ( + ) enantiomers of [3H]CF and [18F]CF was measured in vitro and the results were similar (Kawai et aI., 1990b) ; a value of 1.3 was used for both enantiomers in Eq. (3) and assumed to remain con stant throughout all studies.
Correction for radioactivity in the vascular space
The measured radioactivity in dissected brain samples (Am) is the sum of tissue (AT) and vascular (Ay) compo nents:
(4) Radioactivity in the vascular compartment Ay can be de scribed by (5) where Vy is the volume of the vascular space (Blasberg et aI., 1983) , and Cu and CM are the blood concentrations of unchanged CF and radiolabeled metabolites, respec tively. Since radiolabeled metabolites of eHJ-and [18F]CF were shown to be polar and do not cross the BBB (Blasberg et aI., 1989; Sawada et aI., 1990b) , the concen tration of radiolabeled metabolites (C M ) would be the same as that in arterial blood. The concentration of CF in the vascular space (C u) can also be assumed to be equal to that in arterial blood since all of the tissue radioactivity values were measured under steady-state or near steady-state conditions.
Kinetic and eqUilibrium models
The general kinetic model adopted in this study for transport, nonspecific binding, and receptor binding of ( -)-CF is shown in Fig. I . The model consists of four compartments, which correspond to (a) "free" unbound tracer in brain tissue Af (readily available for effiux, and nonspecific and/or specific binding), (b) receptor bound ligand Ap and nonspecifically bound ligand where the binding is both (c) instantaneous, An2, and (d) with mea surable rate constants, An I ' A single site for receptor binding is assumed. The differential equations are dAnl dt = ksAf -klAnl
The compartmental model adopted in this study con sists of free, unbound ligand (AI). receptor-bound ligand (Ar), nonspecifically bound with measureable rate constants (An1) , and "instantaneously" bound (An2)' K1 and k2 are the influx (blood clearance) and efflux rate constants across the blood-brain barrier, respectively; kon and koff are the recep tor association and dissociation rate constants. respectively; Bmax is the concentration of receptors ; k5 and ks are the nonspecific binding association and dissociation rate con stants, respectively; K;q is the "instantaneous" nonspecific binding equilibrium constant. Under linear (t racer) condi tions, receptor association (kon• Bmax) and dissociation (koff) processes can be expressed by k 3 and k4' respectively.
(9)
where K 1 is the influx or blood clearance constant (mil min/g), the term k with subscripts 2, 5, and 6 corresponds to linear kinetic rate constants (mm -1 ) depicted in Fig. I , and k� and k� are rate constants for nonspecific binding with high (nonmeasurable) values where k�/k� = K:q ( Fig. 1 ). The terms kon (l/min/nM), koff (min -I ), and Bmax (pmol/g of tissue) are the biomolecular association and dissociation rate constants and the number of available receptors for (-)-CF binding, respectively. Bmax in this study includes unoccupied receptors and receptors that reversibly interact with endogenous and/or exogeneous substaj1ces within the time frame of the experimental pe riod. Vd is the tissue distribution volume of the free, un bound ligand. In our analysis, the tissue water space (wT = 0.79 ml/g of tissue) (Grome et aI., 1988 ) was assumed to be the tissue volume of distribution Vd of free ligand. Since Eqs. (6) and (7) involve nonlinear terms, the tissue concentration of ligand, AT = (Af + Ar + An I + An2), cannot be analytically obtained (see the simulation sec tion).
In the linear or "tracer" condition, Ar � Bmax and the terms konBmaxlVd and koff in Eqs. (6) and (7) can be replaced by k3 and k4' respectively, yielding
The equation for tissue concentration (AT) in the tracer range was analytically obtained previously (Kawai et aI., 1990b) by solving Eqs. (8)-(11).
At equilibrium, the free, unbound ligand concentra tions in tissue (CfT) and blood (Crn) water are equal as-
suming passive diffusion of the ligand across the tissue capillaries:
where fB' WT, and WB are the free ligand fraction in blood and the water contents in tissue (ml of water/g of brain) and blood (ml of water/ml of blood), respectively. In this equation, we also assume that the pH of extracellular fluid (ECF) is equal to that of plasma (Roos, 197 1) and that the free, unbound ligand in ECF equilibrates with that in the intracellular space. The amount of free ligand that may accumulate in the intracellular space above that in plasma water or ECF due to pH differences or to active transport mechanisms is regarded as a component of non specific tissue binding in our analysis. Practically, CfT can be obtained directly from measurements of plasma ob tained at equilibrium, without the estimation of kinetic parameters: (13) wherefp is the unbound to total CF concentration ratio in plasma as measured by ultrafiltration (ml of plasma/ml of water or ultrafiltrate) (Sawada et aI., 1990b) .
The tissue concentration (AT) at equilibrium was ob tained by setting all of the derivatives in Eqs. (7)-(9) (non linear condition) to zero, rearranging the equations, and inserting Eq. (12): (14) where K D is the equilibrium dissociation constant (kor/ kon) of ligand-receptor interaction and Keq is the equilib rium constant for total nonspecific tissue binding (Keq = ks/k6 + K:q). AT for the tracer condition is
Simulation analysis
The establishment of blood-tissue equilibrium was as� sessed by simulating time courses of blood and tissue concentrations under various experimental conditions. The parameters used for these simulations were obtained from previous linear and nonlinear kinetic studies (Kawai et aI., 1990b; Sawada et al., 1990c) .
Our equilibrium study adopted a combination of i.v. bolus injection and constant i.v. infusion. The blood con centration-time profile in this experiment was simulated by use of the blood elimination parameters obtained after i.v. injection alone (Sawada et al., 1990c) . Two indepen dent blood functions, one after a bolus injection and the other during a constant infusion, were superimposed (Gibaldi and Perrier, 1982) in this simulation. Elimination of CF from the blood was assumed to be dose indepen dent for all of the dose levels examined; this assumption was considered reasonable given the results of Sawada et al. (l990c) .
The tissue concentration-time profile of ( -)-CF in the "tracer" range was simulated by using the linear tissue distribution parameters (K I , K:q, k3, k4, ks, and k6) re-ported by Kawai et aI. (1990b) and a linear kinetic model ( Fig. 1 ). In the nonlinear range, simulations were per formed by solving Eqs. (6)-(9); numerical integration was performed by a fourth-order Runge-Kutta method (Pach ner, 1984) at 1 s intervals. The nonlinear parameters (kon' k O ff' and Bma:,J were obtained from a nonlinear kinetic analysis of i. v. bolus injection experiments of eH]( -)-CF (Sawada et aI., 1990c) ; the other parameters (K1, K!q, ks, and kJ were the same as those for the tracer study de scribed above, assuming no concentration dependency for these processes. The equilibrium level or the percent of "true" equilibrium at each time point was calculated by dividing the simulated tissue concentration by the equilibrium tissue concentration. The tissue concentra tion at "true" equilibrium in the linear range and that in the nonlinear range were calculated from Eqs. (15) and (14), respectively.
Data analysis
The tissue (AT) and blood water (Crn) concentrations of (-)-CF obtained in experiment set (B) were fitted to Eq. (14) using a nonlinear least-square program (Kawai et al., 1985) ; estimates of Ko, Bmax, and Keq were obtained.
Thirty-three independent measurements, ranging from 0.2 to 150 nM blood water concentration of CF (Crn), were included in the analysis for each of nine different brain structures. Two additional nonlinear analyses were performed on the same data to estimate Ko and Bmax using alternative methods to estimate nonspecific tissue binding. Method A is a conventional method; the extent of nonspecific binding in any structure was assumed to be equal to the total tissue binding in a structure devoid of receptors, namely the cerebellum. The receptor-bound ligand concentration (Ar) in a certain structure was cal culated by subtracting the cerebellum concentration (AT.cer) from the total tissue concentration of that struc ture (AT)' Method B is a modification of the above method that assumes differences in nonspecific binding in different brain regions; a factor (F ns) was defined for each structure, which describes the tissue activity ratio of the inert enantiomer, (+ )-CF, in that structure to that in cer ebellum at steady state. The values for Fns in various brain structures were obtained from an i. v. infusion study of eH]( + )-CF (Kawai et aI., 1990b) and ranged from 0.9 to 1.4 (see footnote to Table 3 ). To obtain the correspond ing value of Ar by method B, F ns for a certain structure was multiplied by AT•cer; the product represents free and nonspecifically bound ligand in the structure and was sub tracted from AT of the structure to obtain Ar• These two sets of Ar data were fitted by a nonlinear regression pro gram to a single receptor-binding model and Ko and Bmax were estimated:
Ar in this formula is identical to the receptor binding term in Eq. (14).
To evaluate the quality of fit or suitability of the model, a plot of the normalized residuals (Kawai et aI., 1990b ) and Akaike's information criterion (AI C) were obtained (Akaike, 1976) :
where N, SS, and P are the number of data points, sum of weighted squares, and the number of unknown parame ters, respectively. A relative error [l/(response)2] was used as a weighting function. AIC is based on a maximum likelihood estimation and returns a minimum value when the most suitable model is applied in fitting experimental data.
Single point estimation of Bma x
Simultaneously obtained e8F]( -)-CF and [3H]( + )-CF data from experimental set (D) were analyzed by a method that estimates Bmax from a single animal experi ment. The analysis is based on two specific relationships previously confirmed: (a) nonspecific tissue binding Keq is identical for both (+) and (-) enantiomers of CF (Kawai et aI., 1990a,b) ; and (b) (+ )-CF has no affinity to the opiate receptor (Rothman et aI., 1988; Kawai et aI., 1990b) . Under these conditions, the tissue concentration of ( + )-CF [AT ( + l ] at equilibrium can be defined as
where Crr ( + 1 represents the free ( + )-CF concentration in blood water [equal to Crr in Eq. (14)]. This relationship was rearranged and inserted into Eq. (14); the following equation for Bmax was obtained:
where AT and Crr in Eq. (14) were redefined as AT(-l and Crr ( -l , respectively. The term in the first bracket refers to the extent of receptor saturation and approaches unity when Crr ( -l ;,:. Ko; the inverse of this term was defined as the percent saturation: (20) We performed two analyses to estimate Bmax: (a) com plete (100%) saturation was assumed, regardless of the measured value of Crn (Crr) , and the KdCrr ( -l ratio in Eq. (19) was set to zero; and (b) the value of Ko obtained from a separate set of experiments (set B, Table 2 ) was used in Eq. (19); thus, the Bmax estimate was corrected for the level of receptor saturation.
RESULTS
The radioligand was administered by i. v. bolus injection plus constant i. v. infusion in order to achieve a rapid equilibrium between blood and brain tissue. This administration sequence was used in all studies and provided high initial blood levels to facilitate loading of the tissue, followed by con stant blood levels to achieve tissue-blood equilib rium .
Constancy of blood CF
The concentration of CF in blood after i. v. injec tion and constant i. v. infusion was simulated (Fig.  2) . The kinetic parameters used for the blood clear ance simulation were obtained previously from the analysis of i. v. bolus injection experiments (Sawada et al., 1990c) . A bolus/infusion (H/I) ratio of 45/55 (injected amount vs . infused amount/h) was shown to produce a constant blood concentration between 20 and 90 min. Other H/I ratios resulted in a pro- concentration was also measured in the nonlinear tissue binding study (set B) and the constancy of blood levels was found to be unaffected by CF con centration in the dose range studied. Mean blood concentrations at 30, 45, and 60 min were 0.080 ± 0.015, 0.082 ± 0.016, and 0.082 ± 0.017% of the bolus dose/ml of blood (mean ± SD; n = 6), respec tively, in the highest dose group (200-450 nmol/rat) . All subsequent simulations and in vivo experiments used the 45/55 B/I administration schedule.
Establishing tissue-blood equilibrium
The tissue concentration of' 'tracer" ( -)-CF dur ing i. v. B/I administration was also simulated. The simulation was performed using the measured blood curve shown in Fig. 3 and the rate constants for tissue distribution of ( -)-CF obtained in a previous study (Kawai et aI., 1990b) . The simulated time courses of tissue concentration, tissue-to-blood concentration ratio, and the equilibrium level (per cent of true equilibrium) are shown in Fig. 4 . Three brain regions-thalamus, cerebellum, and parietal cortex-are representative of a receptor-abundant, a receptor-absent, and an intermediate structure in rats, respectively. The tissue concentration of ( -)-CF in cerebellum was shown to overshoot the equilibrium level shortly after the bolus injection, while ( -)-CF in the other two structures progres sively increased toward the equilibrium value. Equilibrium was reached rapidly in cerebellum and parietal cortex; the simulated tissue concentrations and the tissue-to-blood concentration ratios were within ±2% of the equilibrium value after 45 min. The concentration of ( -)-CF in thalamus increased more gradually; at 45, 60, and 90 min, the simulated tissue levels were 82, 88, and 93% of the equilibrium value, respectively. "Tracer" amounts (0.01-0 .02 nmol) of [ Hl F] _ ( -)-CF were administered to rats using the same 45155 B/I administration ratio and the tissue and blood concentrations were measured at 45, 60, and 90 min in experiment set (A). The results were cor rected for radiolabeled metabolites in blood and are expressed as a tissue-to-blood concentration ratio ( Table I) . The experimentally measured values of the tissue-to-blood ratios were essentially constant between 45 and 90 min in all structures. They are similar to the equilibrium values estimated from a kinetic analysis of constant i. v. infusion experi ments (Kawai et aI. , 1990h) . In thalamus, the changes between 45 and 90 min were smaller than those predicted by the simulation (Fig. 4) ; experi mentally, the average tissue-to-blood concentration ratio increased less than 4% from 45 to 90 min, whereas a 13% increase was expected from the sim ulation.
Attainment of tissue equilibrium for a "non tracer" dose range (2.4-1000 nmollrat) was also ex amined by simulation. The nonlinear parameters (Bmax , kon' and koff) obtained from a previous in vivo study (Sawada et aI., 1990c) were used for this calculation. The simulated time course of tissue concentration, tissue-to-blood concentration ratio, and equilibrium level for fo ur different doses are shown in Fig. 5 . The simulations illustrate that the distribution of CF in thalamus and parietal cortex is dose dependent and that an increase in dose results in a more rapid attainment of tissue-blood equilib rium in these structures. In contrast, the distribu tion of CF in cerebellum and the time to reach tis sue-blood equilibrium in this structure is dose in dependent. The tissue levels for all of the structures would be expected to be within ±3% of the equi librium value by 60 min for the concentration range examined.
Comparison of CF concentration in CSF and plasma water
The concentration of eH]( -)-CF and eH] (+ )-CF in CSF was measured 60 min after i.v. B/I administration [experiment set (C)]. The free, un bound fraction of CF isomers in plasma ifp) was also measured at the beginning of each experiment and ranged from 0.64 to 0.74. No dose-dependent plasma protein binding was observed for ( -)-CF in the concentration range studied. These values are very similar to the in vitro measurements reported by Sawada et al. (l990a, h) and Kawai et al. (1990a) . The CSF concentration was compared with the free, unbound concentration of CF in plasma water (Fig. 6 ) . An excellent correlation was observed be tween these measurements over a wide dose range [2.4-250 and 4 nmollrat for (-) and (+ ) enantio mers, respectively].
Receptor binding kinetics in vivo
The tissue concentration of eH]( -)-CF was mea sured in various brain structures and in plasma wa ter at 60 min following i. v. B/I administration over a dose range of 2.4-400 nmollrat [experiment set (B) ]. The relationship between tissue (-)-CF and the free, unbound concentration in plasma water is shown in Fig. 7 for three representative structures. In the low concentration range « 1 nM), the tissue concentration increased linearly with increasing "free" plasma ( -)-CF and large differences were observed between brain structures ( Fig. 7 A) . Lin ear relationships were also observed in the high concentration range (> 10 nM) for all of the struc tures (Fig. 7B) . Nonlinear relationships were ob- served for thalamus and parietal cortex in the con centration range of 1-10 nM, whereas a continuous linear relationship was observed for cerebellum ( Fig. 7 A,B) . These tissue and plasma concentration data were fitted to a single receptor model [Eq. (14) ] by a non linear least-square regression program (Kawai et aI., 1985) ; the nonspecific binding equilibrium con stant (Ke q ) , the ligand-receptor dissociation con stant (Kn), and the density of opiate receptors (Bmax) were estimated for various brain structures ( Table 2 ). The data for some representative struc tures were also fitted to a two-receptor model (Rothman and McLean, 1988) . Plots of the normal ized residuals showed a random scatter of the data for both models and no noticeable improvement in the fit was observed by an additional receptor site. The value of AIC was always larger in the two re ceptor model for all structures examined. These comparisons suggest that a single receptor model is J Cereb Blood Flow Metab, Vol. 11, No .4, 1991 sufficient to describe the in vivo receptor binding kinetics of (-)-CF in this concentration range (0 . 25-150 nM). The estimates of Kn and Bmax for this model ranged between 1.4-2 .9 nM and 15-74 pmol/g, respectively, for structures in cerebrum.
The value for Ke q was estimated to be between 5.2 and 8.0 for all structures.
Effect of heterogenous nonspecific binding on Bmax and K n estimates
We compared three different approaches to the estimation of nonspecific tissue binding and deter mined the effects of each method on the estimation of receptor binding parameters (Kn and Bmax). The "reference" method allowed for heterogeneous nonspecific binding and involved a nonlinear fit of the data (Fig. 7) to estimate three parameters (Bmax, Kn, and Ke q ); the results are shown in Table 2 . The same data were analyzed by two other methods:
Ke q was determined separately and only two param- eters (KD and Bmax) were estimated in a nonlinear fit of the data. Method A is a conventional method to determine Ke q ; Ke q for all brain structures is defined by the value measured in cerebellum, Ke q , C eP a re gion devoid of opiate receptors in the rat. Method B is a modification of method A where Ke q, cer is mul tiplied by a correction factor, Fns' in order to cal culate Ke q for a specific brain structure (see the Methods section). The results of these two analyses and the values of Fns are shown in Table 3 . Using method A (Table 3) twofold for thalamus and caudate compared to the "reference" values in Table 2 , whereas the esti mates for midbrain, medulla, and white matter were in similar ranges. This would be expected since nonspecific tissue binding, Ke q , in these latter three structures is very similar to that measured in cere bellum (Table 2) . Using method B (Table 3) , the estimates of KD and Bmax for all brain structures were consistent with the parameter estimates in Ta ble 2. These results clearly indicate that the as sumption of homogeneous nonspecific binding can produce substantial analytical errors when estimat ing KD and Bmax. The error was largest in cortex, where nonspecific binding differs most from that in cerebellum.
The effects of an erroneous estimate of nonspe cific tissue binding using these two methods to es timate Ar is also very obvious by comparing the Scatchard plots of Ar and Cf (Fig. 8) . The Scatchard plot of the data using the conventional approach (method A) suggests the presence of a "low affinity" binding component in the receptor-bound fraction, while a Scatchard plot of the same data set using method B depicts a single site for "high affinity" receptor-ligand interaction. of ( -)-CF in plasma water varied from 35 to 65 nM depending on the dose/animal weight and individual variations in blood clearance. The extent of recep tor saturation with CF in this concentration range was calculated [Eq. (20) ] and ranged from 92 to 98%. The Bmax estimates, with a correction for the extent of saturation (11-70 pmol/g of brain tissue) and without the correction (11-65 pmol/g), were nearly identical. They were also similar to the esti mates obtained from experiments using [3H]( -)-CF alone [experiment set (B), Table 2 ]; the correlations between these methods [multipoint (Table 2) and single point estimation] are shown in Fig. 9 . The contribution of receptor binding to total tissue bind ing in these single animal experiments was calcu lated and found to vary from 2 to 36%, depending on the density of receptors in a particular brain structure and on the plasma water concentration of the ligand. assumes heterogeneous nonspecific binding in brain, where Ans = Fns . AT(cerebeIlUm) (see the text and Table 3 ).
DISCUSSION
A derivative of naltrexone (6-deoxy-6(3-flu oronaltrexone; cyclofoxy) has been synthesized and labeled with 18 F and 3H . An initial study using the acetylated 18F analog of ( -)-CF and positron emission tomography (PET) indicated that CF might prove useful for imaging opioid receptors in vivo (Pert et aI., 1984) . Re cently, Ostrowski et al. (1987) showed that the un acetylated compound, eH]( -)-CF, is also retained in opioid receptor-dense brain regions in rats, whereas the inactive enantiomer eH]( + )-CF dis tributed uniformly and at low levels throughout the brain (Kawai et aI., 1990a,b) . More recently, Roth man et al. showed that CF labels mu and kappa 2.9 ± 0.4 0.95 White matter 10 ± 1 1.0 ± 0.3 16 ± 2 1.9 ± 0.5 0.93 a The data set analyzed in Table 2 was reanalyzed using two different methods to estimate nonspecific tissue binding. b Conventional method: nonspecific tissue binding of [3H)( -)-CF was assumed to be uniform throughout the brain and equal to that in cerebellum (Ans , cerebellum) , a structure devoid of opiate receptors in the rat.
C Modified method: nonspecific tissue binding of eH)( -)-CF in different brain structures (Ans . structure) was assumed to be heteroge neous; it was calculated by Ans structure = F ns structure . Ans cerebellum ' d Fns was calculated from steady-state mea�urements o([3H)( + )-CF (Kawai et aI., 1990b) ; Fns, structure 0 + Keq, structure)/O +
Keq, cerebellum)'
e Estimated values, ± SEM of the estimate. opioid binding sites in vitro and in vivo, and con cluded that CF is suitable for labeling opioid recep tors using PET (Rothman et aI., 1988; Rothman and McLean, 1988) . were able to estimate kinetic parameters for BBB transport, nonspecific tissue binding, and opiate re ceptor binding in different brain structures. In ad dition, Sawada et al. (1990c) obtained in vivo esti mates of Ko and Bmax in various brain structures from time-activity data that was obtained following i. v. injection of different doses of eH]( -)-CF. Two limitations of these studies can be noted. First, a tissue and blood time-activity profile had to be measured in each of the studies and the data were processed by curve-fitting analysis in which a spe cific compartmental model for ( -)-CF distribution in the tissue had to be assumed. Second, the initial blood clearance of ( -)-CF following i. v. injection was very rapid; insufficient frequency of blood sam pling and small timing errors under these conditions could result in large errors in the measured arterial input function and estimated parameters (Sawada et aI. , 1990c) .
In the present study, we extended our in vivo investigations of this opiate receptor ligand with the aim of developing a simpler and more clinically use ful method to estimate Ko and Bmax in different brain regions. To accomplish this goal, we con sidered equilibrium studies to be the most direct experimental approach to obtain reliable mea surements for estimating these receptor-binding parameters. The rapid establishment of "true" equilibrium between blood and tissue with respect to "free" and bound CF in different brain struc tures was the first operational goal in this study. To establish equilibrium rapidly in vivo, we adopted an administration schedule that involved a combina tion of bolus i. v. injection and constant i. v. infusion (Frey et aI., 1984; Carson et aI., 1989) .
Consideration of equilibrium
"True equilibrium" is established when the net transport of ligand between all physiological com partments (e.g., free, nonspecifically bound, or re ceptor-bound pools) ceases. In many studies, a "constant ratio of the tissue-to-blood concen tration" has been interpreted as equilibrium. This "transient equilibrium" can be produced by tissue and blood levels changing at identical rates whether or not a true equilibrium is achieved for receptor ligand interaction. The tissue-to-blood ratio during transient equilibrium may differ significantly from the true equilibrium value (Carson et aI. , 1989) . We therefore designed our experiments so that the blood concentration was maintained constant for at least 30 min before the tissue measurement.
A programmed infusion technique was originally introduced by Patlak and Pettigrew (1976) in order to establish a constant blood level of a drug and has been used with and without modifications by vari ous investigators (Sokolof et aI. , 1977; Frey et aI. , 1984; Carson et aI., 1989; Dubey et aI. , 1989) . We chose an i. v. bolus injection/i. v. infusion adminis tration schedule (B/I) in order to provide high blood levels initially to facilitate "loading" brain regions with a high density of opiate receptors (e. g. , thala mus) and to provide constant blood levels later in order to achieve true equilibrium. With constant in fusion alone, Kawai et al. (1990b) measured a tis sue-to-blood concentration ratio in thalamus that was less than 70% of the equilibrium value at 60 min, whereas with a B/I administration ratio of 45/ 55, about 90% of the equilibrium value was achieved (Fig. 4) . A more rapid and closer approx imation of equilibrium for this brain region might have been established by use of a different B/I ratio, namely more bolus and less infusion. However, this would require a longer time to achieve a constant blood concentration in this case (Fig. 2) .
In general, larger values of k4 and smaller values of k3 (or a smaller receptor binding potential; BPr = k3/k4) allow the tissue to reach equilibrium in a shorter time period. This tendency was reflected in our simulations of different tissue concentration-time profiles (e. g., thalamus and parietal cortex in Figs. 4 and 5) . Similarly, partial and complete sat uration of the receptor site would be expected to facilitate attainment of tissue equilibrium since re ceptor saturation reduces the apparent magnitude of k3 and BPr. At higher dose levels, the tissue dis tribution-time profiles of receptor-rich structures (Fig. 5A and B ) become similar to that of cerebel lum (a receptor-absent and "dose-independent" structure ; Fig. 5C ). Our simulations show that for a total dose of more than 2.4 nmol/rat, all brain struc tures studied were within ±3% of the true equilib rium values [Eq. (14) ] by 60 min. Accordingly, we assumed that all of the tissue and blood measure ments in the experimental sets B, C, and D (see the Materials and Methods section) represent true (100%) equilibrium values.
Estimation of "free" ligand concentration in the tissue
The concentration of available ligand for receptor binding, namely the concentration of free, unbound ligand in tissue water, is an important determinant for the accurate estimation of Ko . However, this concentration is usually unmeasurable. We have as sumed that the ligand concentration in ECF is the critical concentration in this and our previous tracer kinetic studies, and that this concentration can be closely approximated by measuring the free, un bound concentration in blood or plasma water (Blasberg et aI. , 1989; Kawai et aI. , 1990a.b; Sawada et al., 1990b) . This assumption seems rea sonable considering the anatomical location of opi ate receptors on the surface of the cell membrane (Pert et al. , 1975) and the negligible amounts of pro tein in brain ECF. Experimental confirmation of equivalent concentrations of free, unbound ligand in brain ECF and blood under equilibrium condi tions has recently been shown for a benzodiazepine using microdialysis techniques (Dubey et al. , 1989) .
In this equilibrium study, we demonstrated a con sistent 1: 1 relationship between the concentration of CF in CSF and plasma water over a wide con centration range. Brain ECF and CSF are known to have very similar components and the pH of these fluids is very close to the pH of plasma under nor mal conditions (Roos, 197 1). Thus, the concentra tion of lipophilic and highly diffusable ligands, such as CF, should be identical in these two biological fluids under equilibrium conditions. These results strongly support a passive diffusion mechanism for BBB transport of CF and suggest that the free, un bound concentration in tissue can be closely ap proximated by measuring the unbound concentra- Vol. 11, No . 4, 1991 tion of CF in plasma water at equilibrium [Crr; Eq. (13)].
Analysis of binding sites and estimation of Ko
and Bma x Rothman and McLean (1988) reported that ( -)-CF labels both mu and kappa subtypes of the opiate receptor on the basis of in vitro experiments ; their estimates of KD for the two subtypes differed by a fa ctor of four (0. 34 and 1.5 nM for mu and kappa respectively). From an analysis of our in vivo experiments with ( -)-CF, we could detect only one receptor site. We performed both one-and two receptor model fits of the same data and the result ant AIC values and normalized residual plots indi cated that a single-receptor model is preferable for the analysis of in vivo experiments using (-)-CF (data not shown).
The dissociation constant (Ko) in the single receptor model was estimated within a narrow range 0.4-2.9 nM) for various structures in the ce rebrum; these values are similar to or slightly larger than the in vitro estimations of Ko (Rothman and McLean, 1988) . Two factors may have influenced our results and account for these small differences in Ko. First, the equilibrium concentration of ligand in plasma water ranged from 0. 25 to 150 nM and might not be appropriate to detect a very-high affinity binding site. Second, endogenous opiate peptides and other competitive substances are likely to exist in vivo and may increase our regional estimates of Ko .
Receptor density (Bmax) estimates are more diffi cult to compare between in vitro and in vivo exper iments. An average value of Bmax in cerebrum was obtained in vitro (Rothman and McLean, 1988) , and an approximate value of 12 pmol/g of tissue was calculated for the sum of mu and kappa subtypes using an appropriate slice-to-whole brain conver sion factor (Rothman et al. , 1983) . This in vitro Bmax value is similar to our in vivo estimates in cortex, hippocampus, and white matter, but severalfold less than that obtained in the midzonal structures (thalamus and caudate). Since the volume of these receptor-abundant structures are small compared to the total cerebrum, the average value of Bmax for cerebrum in vivo is only slightly larger than that obtained in vitro. Furthermore, experimental re covery and/or postmortem degradation of the re ceptor protein in the in vitro system may also con tribute to the small difference in Bmax values. Sawada et al. (l990c) 79 pmol/g of tissue in cerebrum) were similar to those of the present equilibrium measurements. The value of Ko was similar or slightly larger (2.1-S.6 nM) than in the present study, although a large error was associated with the Ko estimates of Sawada et al. (1990c) . These comparisons suggest that the three-compartment model used by Sawada et al. (1990c) is appropriate and can be used to estimate the nonlinear receptor-binding parameters (Ko and BmaJ following i. v. injection of (-)-CF.
can be expected to be more serious under nonlinear or near-saturation conditions where the contribu tion of nonspecific binding to total measured activ ity is high.
Most estimates of Bmax and Ko in human subjects have been made from steady-state or equilibrium experiments involving only two or three different concentrations of the neuroligand or competitive in hibitor (Wong et aI., 1986b; Farde et aI., 1989) . These studies had to employ Scatchard or other lin earization plots in order to estimate Ko and Bmax from the limited amount of data. It is very likely that systematic errors, such as the one described above for nonspecific tissue binding (Table 3 , method A and Fig. 8, panel A) , could occur and not be recognized in the analysis of a small data set . Yet, such systematic errors could have a substantial effect on the calculated values of Ko and Bmax . For example, the effect of an erroneous estimate of non specific tissue binding will have a proportionately greater effect in structures with a low number of receptors (Table 3 ). An accurate assessment of non specific tissue binding will also assume greater im portance in the analysis of data from subjects with particular disease states or treatment regimens in volving receptor-specific drugs that lower receptor density and/or reduce the number of unoccupied receptors .
In addition to the analytical pitfalls noted above, recent in vitro studies by Gibo et ai . (1990) indicate that the subtypes of the opiate receptor (including mu and kappa) in the cerebellum are not always negligible but should be carefully evaluated depend ing on species and age. Consequently, the receptor inert enantiomer, (+ )-CF, is likely to become a more useful ligand, provide an independent mea sure of nonspecific binding in different brain struc tures, and contribute to a more accurate assessment of receptor density (mu and kappa subtypes) .
Single study estimate of Bm ax
Receptor-ligand interaction is considered to be a bimolecular, saturable process; the concentration of receptor-bound ligand (Ar) will approach a con stant value (Bmax) when the free ligand concentra tion (Crr) exceeds a certain value. Thus, it is theo retically possible to estimate Bmax from a single equilibrium measurement providing Crr is suffi ciently high (Crr ;,::. K 0) ' Experimentally, the ac tual measurement of tissue activity (AT) does not approach a constant value but increases with an increase in the plasma concentration of the ligand (Fig . 7B) ; the slope or rate of increase depends on the extent of nonspecific and nonsaturable tissue binding.
J Cereb Blood Flow Metab. Vol. 11, No . 4. 1991 The method we propose to obtain a single study estimate of Bmax requires a very accurate assess ment of nonspecific tissue binding, since Bmax is obtained from a comparatively small difference be tween two measurements of radioactivity. To facil itate this approach, we performed double-label equilibrium-type experiments using eSF]( -)-CF and the receptor-inert enantiomer eH]( + )-CF . It is obvious that tissue-blood equilibrium of (+ )-CF will be achieved rapidly in all brain regions using the same B/I (45/55) administration schedule de scribed above for ( -)-CF since (a) the blood clear ance of ( + )-CF was found to be identical with that of ( -)-CF (Kawai et aI ., 1990b) , (b) the BBB trans port parameters of ( -)-CF and ( + )-CF were iden tical (Kawai et aI., 1990a) , and (c) tissue binding of ( + )-CF in various brain regions was the same as that obtained with a receptor saturation dose of (-)-CF (1 mg/rat) (Kawai et aI., 1990b) . Therefore, the tissue concentration-time profile of ( + )-CF af ter B/I administration will be identical to that of ( -)-CF when the receptor is completely saturated (Fig. 5 ) .
An important question we had to address was as follows: What concentration range of free, unbound ( -)-CF in plasma is best to obtain a reasonable estimate of Bmax ? Too high a concentration will re sult in large experimental errors due to a very small difference between the [ l sF]( -)-CF and eH]( + ) CF measurements . Too Iow a concentration will re sult in incomplete saturation of the receptor sites .
The dissociation constant (Ko) provides a basis for selecting an appropriate concentration range . For example, a concentration of ligand 10 to 20 times the K 0 value will saturate and label 90 to 95% of the available receptor sites. We used an average Ko of 2 nM and calculated an unbound ligand concentra tion that would saturate approximately 95% of available receptors. Under these conditions, the nonspecific binding component was severalfold larger than the receptor-binding component of eSF]( -)-CF in all brain structures. Nevertheless, we could obtain measurements of nonspecific tissue binding [Ans, eH]( + )-CF] and total tissue binding [AT' eSF]( -)-CF] under near-saturation (92-98%) conditions with sufficient accuracy to obtain single animal estimates of Bmax . These Bmax values were consistent with those reported in Table 2 (see Fig.  9 ) and those obtained from i. v. bolus injection stud ies (Sawada et aI., 1990c) .
This result indicates that the estimation and the subtraction of nonspecific binding using ( + )-CF is quite accurate and that this method may be useful in other experimental paradigms to measure regional opiate receptor density in individual animals. The single study method is particularly advantageous where the experimental state or condition is diffi cult to reproduce and a time-concentration profile cannot be measured in a single subject. Further more, this approach could be adapted to investigate opiate receptors in human subjects using sequential administrations of ll C_ or 18 F-Iabeled ( + )-CF and ( -)-CF and positron emission tomography.
